HK1204967A1

HK1204967A1 - Composition containing natural plant extracts as active ingredients, external skin preparation comprising the same, cosmetic preparation comprising the same and pharmaceutical preparation comprising the same

Info

Publication number: HK1204967A1
Application number: HK15105754.8A
Authority: HK
Inventors: 金炫廷; 梁美淑; 申辰燮; 金漢別; 金汉别; 黄晶俄; 李真鍈
Original assignee: 株式会社爱茉莉太平洋
Priority date: 2013-11-19
Filing date: 2015-06-17
Publication date: 2015-12-11
Also published as: CN104644494B; CN104644494A; KR102142318B1; SG10201407739UA; KR20150057378A; TW201601774A; TWI663989B

Abstract

The present invention relates to a composition containing natural plant extracts as effective constituents, an external skin preparation comprising the same, a cosmetic preparation comprising the same and a pharmaceutical preparation comprising the same. The present invention relates to the composition containing cymbidium kanran extracts and more than one extracts selected from the green tea, the pharmacal action, the bletilla striata and the cactus as the effective constituents, the external skin preparation comprising the above composition, the cosmetic preparation comprising the above composition and the pharmaceutical preparation comprising the above composition.

Description

Composition containing natural plant extract as active ingredient, and external preparation for skin, cosmetic and pharmaceutical agent containing the same

Technical Field

The present invention relates to a composition containing a natural plant extract as an active ingredient, a skin external preparation comprising the same, a cosmetic comprising the same, and a pharmaceutical preparation comprising the same, and more particularly, to a composition containing an extract of cymbidium kanran and one or more extracts selected from the group consisting of green tea, camellia leaves, bletilla striata, and cactus as active ingredients, and having antioxidant and anti-inflammatory effects.

Background

Known inflammatory skin diseases include allergic dermatitis (atopic dermatitis), contact dermatitis (contact dermatitis), seborrheic dermatitis (seborrhoic dermatitis), acne, etc.

Generally, human keratinocytes or islet cells are excreted by external substances producing various cytokines from the viewpoint of the mechanism of the stimulation response or the inflammatory response. This cytokine is essential for inducing skin irritation or local inflammatory reaction as an immune system activation-promoting substance in the human body (J Appl Toxicol 16:65-70,1996). In fact, it has been reported that Interleukin-6 (Interleukin-6; IL-6), Interleukin-1 (Interleukin-1; IL-1), Tumor necrosis factor-alpha (Tumor necrosis factor-alpha; TNF-alpha) are increased in irritant Contact Dermatitis (Contact Dermatitis 35: 355-60, 1996, Dec).

To date, antihistamines, vitamin ointments, and corticoids have been mainly used for the treatment of inflammatory skin diseases such as those described above, but the effects thereof are mostly temporary and have serious side effects.

Therefore, there is a need for a composition that can effectively cope with oxidative and inflammatory diseases that may occur on the skin, and contains a natural plant extract as an active ingredient without side effects on hormonal drugs and the like.

[ Prior art documents ]

[ patent document ]

(patent document 1) Korean patent laid-open publication No. 10-2013-0031988 (2013.04.01)

Disclosure of Invention

Technical problem to be solved

The present invention provides a composition containing various natural plant extracts as active ingredients and having antioxidant and anti-inflammatory effects, and a skin external preparation, a cosmetic and a medicament containing the same.

Technical scheme

The present invention relates to a composition containing an extract of cymbidium kanran and one or more extracts selected from green tea, camellia leaves, bletilla striata and cactus as active ingredients.

Also, the present invention provides an external preparation for skin comprising the composition.

Also, the present invention provides a cosmetic comprising the composition.

Also, the present invention provides a medicament comprising the composition.

Advantageous effects

The composition according to the present specification contains 2 or more natural plant extracts as active ingredients, and has an outstanding antioxidant effect of removing active oxygen and an anti-inflammatory effect of reducing skin inflammatory diseases, compared to a composition containing 1 single natural plant extract as an active ingredient.

Drawings

FIG. 1 shows the TNF-. alpha.evaluation results of the compositions of comparative examples 1 to 5 and examples 1 to 5 in test example 1.

FIG. 2 shows the results of evaluation of IL-6 in each of the compositions of comparative examples 1 to 5 and examples 1 to 5 in test example 2.

Detailed Description

Herein, cymbidium kanran means cymbidium kanran (cymbidium kanran) which is a perennial herb in the family orchidaceae.

In the present specification, green tea refers to a substance prepared by using shoots or leaves of tea trees (Camellia Sinensis) of the family Camellia Sinensis, and inactivating enzymes by treating oxidase present in the tea leaves with fire heat or steam.

In the present specification, Camellia refers to Camellia (Camellia japonica) of the family Camellia sinensis.

In the present specification, Bletilla striata means Bletilla striata (Bletilla striata) of the family orchidaceae.

In the present specification, cactus denotes cactus (Opuntia Coccinellifera) of the family cactaceae.

The cymbidium kanran extract, the green tea extract, the camellia japonica extract, the bletilla striata extract and the cactus extract can be prepared according to the conventional method known in the field, namely, the cymbidium kanran extract, the green tea extract, the camellia japonica extract, the bletilla striata extract and the cactus extract can be prepared under the conventional temperature and pressure conditions by using the conventional solvent. Preferably, the extraction is carried out using an extraction solvent selected from the group consisting of water, anhydrous or hydrous lower alcohols of C1-C4, acetone, ethyl acetate, butyl acetate, glycerol, 1, 3-butanediol, 1, 2-propanediol and 1, 3-propanediol.

The cymbidium kanran extract can be extracted using the whole herb of cymbidium kanran, i.e., using the whole herb (the same below). The bletilla striata extract can be extracted from the whole plant of the bletilla striata.

The green tea extract can be extracted from the leaves of the green tea. The camellia leaf extract can be extracted by using leaves of the camellia.

The cactus extract may be extracted using the fruit of the cactus.

According to one embodiment of the present disclosure, the composition contains an extract of cymbidium kanran and an extract of green tea as active ingredients.

The composition comprises the cymbidium kanran extract and the green tea extract, so that the antioxidant effect of the composition with more than 2 natural plant extracts as effective components can be improved to the maximum extent.

According to one embodiment of the present specification, the composition comprises an extract of cymbidium kanran and an extract of bletilla striata as effective ingredients.

The composition comprises the cymbidium kanran extract and the bletilla striata extract, so that the anti-inflammatory effect of the composition in the aspect of TNF-alpha inhibition can be improved to the maximum extent, wherein the composition takes more than 2 natural plant extracts as active ingredients.

According to one embodiment of the present specification, the composition comprises an extract of cymbidium kanran and an extract of cactus as effective ingredients.

In the composition, a composition comprising an extract of cymbidium kanran and an extract of cactus are mixed, which can maximize the anti-inflammatory effect in terms of TNF- α inhibition, relative to a composition comprising separate extracts of natural plants.

In the composition, a composition comprising an extract of cymbidium kanran and an extract of cactus are mixed, which can maximize the anti-inflammatory effect in terms of IL-6 inhibition, relative to a composition comprising separate extracts of natural plants.

According to one embodiment of the present specification, the composition comprises an extract of cymbidium kanran and an extract of green tea as active ingredients.

In the composition, the cymbidium kanran makino extract and the green tea extract are mixed and contained, so that TNF-alpha inhibition and IL-6 inhibition which take more than 2 natural plant extracts as effective components can be improved to the maximum extent, and the anti-inflammatory effect can be improved to the maximum extent.

According to one embodiment of the present specification, the composition comprises green tea extract, cymbidium kanran extract, camellia japonica leaf extract, bletilla striata extract and cactus extract as effective ingredients.

In the composition, the mixture contains green tea extract, cymbidium kanran makino extract, camellia japonica extract, bletilla striata extract and cactus extract, so that the anti-inflammatory effect and the antioxidant effect can be improved to the maximum extent.

According to one embodiment of the present specification, the composition comprises 0.0001 to 10 wt% of the cymbidium kanran extract, more specifically, 0.01 to 5.0 wt% of the total weight of the composition. If the content is 0.0001 wt% or more, the antioxidant effect and the anti-inflammatory effect of the above cymbidium kanran extract can be obtained, and if the content is 10 wt% or less, the effect is more effectively increased and is more effective, rather, the content is increased.

According to one embodiment of the present description, the composition comprises 0.0001 to 90 wt% of the green tea extract, more specifically 0.01 to 90 wt%, based on the total weight of the composition. If the content is 0.0001 wt% or more, the antioxidant effect and the anti-inflammatory effect of the green tea extract can be obtained, and if the content is 90 wt% or less, the effect is more effectively increased and more effective, as opposed to increased content.

According to an embodiment of the present specification, the composition comprises 0.0001 to 90 wt% of the camellia leaf extract, more specifically 0.01 to 90 wt% of the camellia leaf extract, based on the total weight of the composition. When the content is 0.0001 wt% or more, the antioxidant effect and the anti-inflammatory effect of the camellia leaf extract can be obtained, and when the content is 90 wt% or less, the effect is more effective and more effective, compared with the increase of the content.

According to an embodiment of the present disclosure, the above composition comprises 0.0001 to 10 wt% of the bletilla striata extract, more specifically 0.01 to 5 wt%, based on the total weight of the composition. When the content is 0.0001 wt% or more, the antioxidant effect and the anti-inflammatory effect of the bletilla striata extract can be obtained, and when the content is 10 wt% or less, the effect is more effectively increased relative to the increase of the content, and the effect is more effective.

According to one embodiment of the present disclosure, the above composition comprises 0.0001 to 90 wt% of the cactus extract, more specifically, 0.01 to 90 wt%, based on the total weight of the composition. If the content is 0.0001 wt% or more, the antioxidant effect and the anti-inflammatory effect of the cactus extract can be obtained, and if the content is 90 wt% or less, the effect is more effectively increased and more effective, as opposed to increased content.

According to one embodiment of the present description, the composition is for use against oxidation. The antioxidant composition contains at least 2 kinds of extracts contained in the composition as active ingredients, and has the effect of reducing or inhibiting free radicals in the skin.

According to one embodiment of the present description, the composition is for anti-inflammatory use. The anti-inflammatory composition comprises more than 2 extracts contained in the composition as effective components, and has the effects of inhibiting or reducing interleukin-6, interleukin-1 and tumor necrosis factor-alpha.

The present invention provides an external preparation for skin comprising the aforementioned composition.

The external preparation is a concept including all preparations suitable for external use, and includes preparations absorbed through the skin, that is, skin absorbents.

According to one embodiment of the invention, the skin comprises ocular skin.

According to an embodiment of the present invention, a specific formulation of the skin absorbent may be exemplified by, but not limited to, a powder for external use, a tablet for external use, a liquid for external use, a patch, a microneedle, an ointment, or a suppository.

The invention provides a cosmetic comprising the composition.

The cosmetic may be formulated with a cosmetically or dermatologically acceptable carrier or mechanism. This is all formulations suitable for topical use, and may be provided, for example, in the form of solutions, gels, solids, anhydrous pastes, emulsions obtained by dispersing an oil phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or dispersions of ionic (liposomes) and nonionic vesicles, or in the form of creams, lotions, ointments, sprays or concealer sticks. Also, it may be used in the form of a foam (foam) or an aerosol composition further comprising a more compressed propellant. The cosmetic may be prepared according to methods commonly used in the art.

Also, the cosmetic may include a fatty substance, an organic solvent, a dissolving agent, a concentrating agent, a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic or non-ionic emulsifier, a filler, a chelating agent, a complexing agent, a preservative, a vitamin, a blocking agent, a humectant, an essential oil, a dye, a pigment, a hydrophilic or lipophilic active agent, a lipid vesicle or an auxiliary agent commonly used in the cosmetic or dermatological science field, etc. together with any other ingredient, etc. commonly used in cosmetics. The adjuvant is introduced in an amount generally used in the field of cosmetics or skin science.

The invention provides a medicament comprising the composition.

The composition may further comprise preservatives, stabilizers, wettable powders (water-dispersible-powder) or emulsion-promoting agents, pharmaceutical adjuvants such as salts and/or buffers for regulating osmotic pressure, and other substances for therapeutic use, and may be formulated in various oral or non-oral forms according to conventional methods.

Examples of oral dosage forms include tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, granules and the like, and these dosage forms contain, in addition to the active ingredient, diluents (e.g., lactose, glucose, sucrose, mannitol, sorbitol, cellulose and glycine), lubricants (e.g., silica gel (silica), talc, stearic acid and its magnesium or calcium salts and polyethylene glycol). The tablet may further contain a binder such as magnesium aluminum Silicate (Magesium aluminum Silicate), starch paste, gelatin, tragacanth (tragacanth), methylcellulose, sodium carboxymethylcellulose, and polyvinylpyrrolidone (polyvinylpyrrolidone), and may contain a pharmaceutical additive such as a disintegrant such as starch, agar, alginic acid (or a sodium salt thereof), an absorbent, a coloring agent, a flavoring agent, and a sweetening agent, as the case may be. Tablets may be prepared by conventional mixing, granulating or coating methods. Also, a representative non-oral dosage form is an injectable dosage form, preferably an isotonic aqueous solution or suspension.

Hereinafter, the structure and effects of the present invention will be described more specifically by test examples and examples. However, these test examples and examples are provided only for the purpose of enhancing understanding of the present invention and are not intended to limit the scope and scope of the present invention to the following examples.

< comparative example 1> preparation of extract of cymbidium kanran

Mixing 50g of the herb of cymbidium kanran with 950g of purified water, and extracting with hot water at 80 deg.C for 12 hr. The extract was filtered through a 1 μm filter, and then concentrated by evaporation until the amount of the extracted stock solution reached 3.5g to prepare a sample. In the following test examples 1 to 3, 20. mu.g of the above cymbidium kanran extract was used.

< comparative example 2> preparation of bletilla striata extract

Mixing 20g of rhizoma bletilla whole plant with 80g of solvent prepared by mixing refined water and glycerol at a weight ratio of 3:7, and extracting at 25 deg.C for 3 days. The extract was filtered through a 1 μm filter to prepare a bletilla striata extract. In the following test examples 1 to 3, 20. mu.g of the above cymbidium kanran extract was used.

< comparative example 3> preparation of Camellia japonica leaf extract

The camellia leaf extract was prepared using 20g of leaves of camellia japonica instead of the whole herb of cymbidium kanran in comparative example 1, and the other preparation processes were the same as in comparative example 1. In the following test examples 1 to 3, 20. mu.g of the above cymbidium kanran extract was used.

< comparative example 4> preparation of cactus extract

The cactus extract was prepared by using 20g of cactus instead of the whole herb of cymbidium kanran in comparative example 1, and the other preparation processes were the same as in comparative example 1. In the following test examples 1 to 3, 20. mu.g of the above cymbidium kanran extract was used.

< comparative example 5> preparation of Green tea extract

A green tea extract was prepared using 20g of leaves of green tea instead of the whole herb of cymbidium kanran in comparative example 1, and the other preparation processes were the same as in comparative example 1. In the following test examples 1 to 3, 20. mu.g of the above cymbidium kanran extract was used.

< example 1> preparation of Mixed extract of cymbidium kanran and bletilla striata

A mixed extract of cymbidium and bletilla striata was prepared by mixing 10. mu.g of the extract of cymbidium kanran makino of comparative example 1 and 10. mu.g of the extract of bletilla striata of comparative example 2.

< example 2> preparation of Mixed extract of cymbidium kanran and Camellia japonica Linne

Mu.g of the extract of cymbidium kanran of comparative example 1 and 10. mu.g of the extract of camellia japonica of comparative example 3 were mixed to prepare a mixed extract of cymbidium kanran and camellia japonica.

< example 3> preparation of Mixed extract of cymbidium kanran and Opuntia ficus-indica

A mixed extract of cymbidium and cactus was prepared by mixing 10. mu.g of the extract of cymbidium kanran of comparative example 1 and 10. mu.g of the extract of cactus of comparative example 4.

< example 4> preparation of Mixed extract of cymbidium kanran and Green tea

A mixed extract of cymbidium and green tea was prepared by mixing 10. mu.g of the cymbidium extract of comparative example 1 and 10. mu.g of the green tea extract of comparative example 5.

< example 5> preparation of Mixed extract of cymbidium kanran, bletilla striata, camellia leaves, cactus and green tea

A mixed extract of cymbidium kanran, bletilla striata, camellia leaves, cactus and green tea was prepared by mixing 4. mu.g of the extract of cymbidium kanran of comparative example 1, 4. mu.g of the extract of bletilla striata of comparative example 2, 4. mu.g of the extract of camellia leaves of comparative example 3, 4. mu.g of the extract of cactus of comparative example 4 and 4. mu.g of the extract of green tea of comparative example 5.

< test example 1> evaluation of organic radical DPPH

In order to understand the antioxidant effect of the extracts prepared in examples 1 to 5, the DPPH oxidation inhibition effect was compared and measured by the change in absorbance due to the reduction (oxidation of antioxidant) of the organic radical DPPH (1, 1-diphenyl-2-picrylphenylhydrazine; 1, 1-diphenyl-2-piperidinylhydrazyl), thereby evaluating the antioxidant effect. That is, the extracts obtained in examples 1 to 5 and the extracts obtained in comparative examples 1 to 5 were measured for the degree of decrease in absorbance with respect to the control group due to the inhibition of DPPH oxidation, and the concentration showing an absorbance of 50% or less with respect to the absorbance of the control group was evaluated as the effective antioxidant concentration. The effective antioxidant concentration of each extract was measured 3 times for each of the control group and each extract, and the results of the average effective antioxidant concentration and the ratio of the average effective antioxidant concentration to the corresponding extract of the effective antioxidant concentration were summarized as shown in table 1.

TABLE 1

As shown in table 1, it is understood that, when comparative example 2 and example 1, comparative example 3 and example 2, comparative example 4 and example 3, and comparative example 5 and example 4 are compared, respectively, the antioxidant effect of examples 1 to 4 in which the cymbidium kanran extract is mixed is more excellent than that of comparative examples 2 to 5 in which a single type of extract is contained as an active ingredient.

In particular, in comparative example 5 containing a green tea extract as a single active ingredient, it is understood that the increase in antioxidant effect is more excellent in example 4 in which a cymbidium kanran extract is mixed with a green tea extract.

It is also found that the antioxidant effect is best in example 5, which contains the mixed extract of cymbidium kanran makino, bletilla striata, camellia leaves, cactus and green tea as the active ingredient.

< test example 2> evaluation of TNF-. alpha.inhibitory Effect

In order to confirm the TNF- α production inhibitory effect of the extracts prepared in examples 1 to 5, the following experiment was performed with respect to human keratinocyte cell line (human keratinocyte cell line) HaCaT cell line obtained from korean bank.

HaCaT cells were cultured at 1X 10⁴The concentration of cells/well was measured in a 48-well plate incubator (well-plate) and cultured in a cell culture medium (DMEM) containing 10% serum (Biowhittaker, Cat. #12-604F) for 24 hours, and then in a serum-free medium for 24 hours. Total protein (total protein) in the cells thus cultured was measured 3 times and quantified as an average thereof. Culturing the cellsAfter washing 1 time with Phosphate Buffered Saline (PBS), 1. mu.g/ml Lipopolysaccharide (LPS) was added to the medium other than the control group with 100. mu.l of Phosphate Buffered Saline (PBS) added, the Phosphate Buffered Saline (PBS) was removed, and the samples of each extract prepared in examples 1 to 5 and comparative examples 1 to 5 except the control group and the non-treated group were added to a new serum-free medium at a concentration of 10 μm, and then each well was treated with 500. mu.l. The test substance was treated, and after 6 hours, the amount of TNF- α in the medium was quantified by 3 measurements using a TNF- α ELISA assay kit (BDBiosciences, Cat. #555212) after the medium was recovered, and the results thereof are shown in table 2 and fig. 1.

TABLE 2

As shown in table 2 and the graph of fig. 1, comparison of comparative example 2 and example 1, comparative example 3 and example 2, comparative example 4 and example 3, and comparative example 5 and example 4, respectively, revealed that examples 1 to 4, in which the cymbidium kanran extract was mixed, had more excellent anti-inflammatory effects than comparative examples 2 to 5, in which a single type of extract was contained as an active ingredient.

In particular, in comparative example 2 containing a bletilla striata extract as a single active ingredient, it is seen that the enhancement of the anti-inflammatory effect is more excellent in the TNF- α inhibitory effect in the case of example 1 in which a bletilla striata extract is mixed with a cymbidium kanran extract.

Meanwhile, in the case of example 4 in which the green tea extract was mixed with the cymbidium kanran extract in the composition containing 2 kinds of natural plant extracts as the active ingredients, the anti-inflammatory effect was most excellent in the TNF- α inhibitory effect.

It is also found that the anti-inflammatory effect is best in example 5, which contains the mixed extract of cymbidium kanran makino, bletilla striata, camellia leaves, cactus and green tea as the active ingredient.

< test example 3> evaluation of IL-6 inhibitory Effect

IL-6 inhibitory effect was measured in the same manner as in test example 2, except that the amount of TNF-. alpha.in the medium was measured 3 times using a TNF-. alpha.ELISA assay kit (BDbiosciences, Cat. #555212) in test example 2 and the average value thereof was used for the quantification. The results are shown in table 3 and fig. 2.

TABLE 3

As shown in table 3 and the graph of fig. 2, it is understood that, when comparative examples 2 and 1, comparative example 3 and example 2, comparative example 4 and example 3, and comparative examples 5 and 4, respectively, are compared with comparative examples 2 to 5 containing a single type of extract as an active ingredient, in the case of examples 1 to 4 in which a cymbidium kanran extract is mixed, the anti-inflammatory effect is more excellent in the IL-6 inhibitory effect.

In particular, in comparative example 4 containing the cactus extract as a single active ingredient, it is understood that the anti-inflammatory effect is more enhanced in the IL-6 inhibitory effect in the case of example 3 in which the cactus extract is mixed with the cymbidium kanran extract.

Meanwhile, in the case of example 4 in which the green tea extract was mixed with the cymbidium kanran extract in the composition containing 2 kinds of natural plant extracts as the active ingredients, the anti-inflammatory effect was most excellent in the IL-6 inhibitory effect.

Further, it is found that the anti-inflammatory effect is the best in terms of the IL-6 inhibitory effect in the case of example 5 containing a mixed extract of cymbidium kanran makino, bletilla striata, camellia leaves, cactus and green tea as an active ingredient.

Claims

1. A cosmetic composition comprising an extract of cymbidium kanran and one or more extracts selected from the group consisting of green tea, camellia leaves, bletilla striata and cactus as active ingredients.

2. The cosmetic composition according to claim 1, wherein the Cymbidium kanran extract is extracted using the whole plant of Cymbidium kanran.

3. The cosmetic composition according to claim 1, wherein said Bletilla striata extract is extracted using whole herbs of Bletilla striata (Bletilla striata).

4. Cosmetic composition according to claim 1, characterized in that said green tea extract is extracted using the leaves of green tea (Camellia Sinensis).

5. The cosmetic composition as claimed in claim 1, wherein the Camellia leaf extract is extracted using leaves of Camellia japonica (Camellia japonica).

6. The cosmetic composition according to claim 1, wherein the cactus extract is extracted using fruits of cactus (Opuntia Coccinellifera).

7. The cosmetic composition according to claim 1, wherein the above cosmetic composition comprises 0.0001 to 10 wt% of said cymbidium kanran extract, or comprises 0.0001 to 90 wt% of said green tea extract, or comprises 0.0001 to 90 wt% of said camellia leaf extract, or comprises 0.0001 to 10 wt% of said bletilla striata extract, or comprises 0.0001 to 90 wt% of said cactus extract, based on the total weight of the composition.

8. The composition as claimed in claim 1, wherein the composition is used for anti-oxidation.

9. The composition of claim 1, wherein the composition is used as an anti-inflammatory.